Spots Global Cancer Trial Database for estrogen receptor positive (er+)
Every month we try and update this database with for estrogen receptor positive (er+) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery | NCT05914792 | Breast Cancer | 70 Years - | University of Pittsburgh | ||
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | NCT04895358 | Breast Neoplasm... | pembrolizumab paclitaxel nab-paclitaxel liposomal doxor... capecitabine normal saline dextrose | 18 Years - | Merck Sharp & Dohme LLC | |
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | NCT04895358 | Breast Neoplasm... | pembrolizumab paclitaxel nab-paclitaxel liposomal doxor... capecitabine normal saline dextrose | 18 Years - | Merck Sharp & Dohme LLC | |
Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery | NCT05914792 | Breast Cancer | 70 Years - | University of Pittsburgh |